Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award
October 22 2020 - 6:45AM
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug
platform company addressing Alzheimer’s disease (AD), Parkinson’s
disease (PD) and other neurodegenerative diseases, today announced
its Founder and Chief Executive Officer, Maria Maccecchini, Ph.D.,
will receive the 2020 Smart Business Dealmaker Award at the Smart
Business Dealmakers Conference Philadelphia, presented by UBS.
“It is a tremendous honor to receive this year’s
Dealmaker award,” said Dr. Maccecchini. “I want to also acknowledge
the dedicated work of our entire Annovis Bio team, whose
contributions played a critical role in our successful IPO earlier
this year and remain an important part of our ongoing success.”
Smart Business Dealmakers was created by the
Smart Business Dealmakers Institute to serve as a resource for
news, insights, and networking for CEOs of middle-market companies
and their advisers in local markets across the country.
Every year, the Smart Business Dealmakers
Conference (formerly ASPIRE) connects thousands of local
dealmakers — including middle-market CEOs, top PE and VC firms,
major lenders and leading service providers — for a day of
dynamic content and networking in top U.S. business markets.
The award ceremony will take place on Thursday,
October 22, 12:30 p.m. – 1:00 p.m. ET during the all-day online
event.
About Annovis BioHeadquartered
in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a
clinical-stage, drug platform company addressing neurodegeneration,
such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and
Alzheimer’s in Down Syndrome (AD-DS). We believe that we are the
only company developing a drug for AD, PD and AD-DS that inhibits
more than one neurotoxic protein and, thereby, improves the
information highway of the nerve cell, known as axonal transport.
When this information flow is impaired, the nerve cell gets sick
and dies. We expect our treatment to improve memory loss and
dementia associated with AD and AD-DS, as well as body and brain
function in PD. We have an ongoing Phase 2a study in AD patients
and have commenced a second Phase 2a study in AD and PD patients.
For more information on Annovis, please visit the company’s
website: www.annovisbio.com.
Forward-Looking
StatementsStatements in this press release contain
“forward-looking statements” that are subject to substantial risks
and uncertainties. Forward-looking statements contained in this
press release may be identified by the use of words such as
“anticipate,” “expect,” “believe,” “will,” “may,” “should,”
“estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding the
timing, effectiveness and anticipated results of ANVS401 clinical
trials. Forward-looking statements are based on Annovis Bio, Inc.’s
current expectations and are subject to inherent uncertainties,
risks and assumptions that are difficult to predict. Further,
certain forward-looking statements are based on assumptions as to
future events that may not prove to be accurate, including that
clinical trials may be delayed. These and other risks and
uncertainties are described more fully in the section titled “Risk
Factors” in the Annual Report on Form 10-K for the year ended
December 31, 2019 filed with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date, and Annovis Bio, Inc.
undertakes no duty to update such information except as required
under applicable law.
Investor Relations:Dave Gentry, CEORedChip
Companies Inc.407-491-4498Dave@redchip.com
SOURCE: Annovis Bio, Inc.
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
From Sep 2023 to Sep 2024